The present invention pertains to a cell-based medicinal product containing mesenchymal stem cells, and a preparation method therefor. The present invention specifically pertains to a cell-based medicinal product containing mesenchymal stem cells, wherein: a) the mesenchymal stem cells express CX3CL1 in response to an inflammatory cytokine stimulus； and/or b) at least 90% of the mesenchymal stem cells express EGFR and/or ITGA4. The present invention also specifically pertains to a preparation method for a cell-based medicinal product containing mesenchymal stem cells, the method including: a) a step for adding inflammatory cytokines to a culture containing mesenchymal stem cells, and confirming that the mesenchymal stem cells express CX3CL1； and/or b) a step for confirming that at least 90% of the mesenchymal stem cells express EGFR and/or ITGA4.
